VectorY Therapeutics raised additional funding for a neurodegenerative gene therapy program aimed at making antibodies in the brain. The financing supports VTx-002, positioned as an intracerebral antibody-producing strategy designed to address limitations of conventional biologics in the CNS. While specific clinical endpoints were not detailed in the brief, the Series A expansion points to the growing emphasis on delivery platforms that can sustain local pharmacology inside the brain. For the biotech ecosystem, VectorY’s update adds to the competitive landscape for brain-directed gene therapy and highlights how investors are still funding modality-shifting neuroscience approaches.